Last week, Health Minister Khairy Jamaludin said that the government would procure 150,000 treatment packages of a Covid-19 anti-viral drug produced by Merck called Molnupiravir. The drug is being described by many quarters as a gamechanger in the fight against Covid-19. Based on trials conducted so far, the medication was shown to reduce the risk of hospitalization or death by around 50% in patients with mild-to-moderate symptoms of the virus. We get the lowdown on Molnupiravir from Sam Fazeli, Director of Research at Bloomberg Intelligence.

Image credit: Quality Stock Arts / Shutterstock.com

Produced by: Shazana Mokhtar

Presented by: Wong Shou Ning, Philip See, Shazana Mokhtar

This and more than 60,000 other podcasts in your hand. Download the all new BFM mobile app.

Categories:  Business Analysis,  Trends and Forecasts,  Markets,  Politics,  Social Issues,  Health Policy,  Diseases & Conditions,  Mental Health,  Healthy Living,  Fitness,  Medical Innovation and Technology,  law & legal matters,  Science,  Investments

Tags:  Merck,  Covid-19,  Medicine,  Pandemic,  Vaccinations,  Global,